The following is a summary of the Phibro Animal Health Corporation (PAHC) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Phibro Animal Health Corporation reported Q3 2024 net sales of $263.2 million, representing a 7% increase from the same quarter a year prior.

• The company saw different performance across its segments with net sales in the Animal Health segment increasing by 10%, a meager 2% growth in Mineral Nutrition, while Performance Products experienced a decline.

• Adjusted EBITDA saw an increment of $2.3 million due to improved numbers in the Animal Health and Mineral Nutrition sectors.

• The firm recorded 9% rises in both adjusted net income and adjusted diluted earnings per share (EPS).

• The Animal Health division was the star performer this quarter with double-digit growth in the top line.

Business Progress:

• The company is geared up for integrating new colleagues and products from Phibro following its acquisition of Zoetis' medicated feed additive portfolio.

• The Zoetis acquisition is expected to increase Phibro's product diversity, species offerings, and also bolster its earnings along with facilitating debt repayment.

• Phibro is optimistic about sustained growth in its Animal Health business and improvements in the Mineral Nutrition and Performance Products businesses.

• The company reaffirms its initial guidance concerning net sales, adjusted EBITDA, and adjusted diluted earnings per share.

More details: Phibro Animal Health IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.